Display options
Cite
Bonneterre J, Bosq J, Jamme P, et al. Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO Open. 2016;1(4):e000072doi: 10.1136/esmoopen-2016-000072.
Bonneterre, J., Bosq, J., Jamme, P., Valent, A., Gilles, E. M., Zukiwski, A. A., Fuqua, S. A., Lange, C. A., & O'Shaughnessy, J. (2016). Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO open, 1(4), e000072. https://doi.org/10.1136/esmoopen-2016-000072
Bonneterre, Jacques, et al. "Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort." ESMO open vol. 1,4 (2016): e000072. doi: https://doi.org/10.1136/esmoopen-2016-000072
Bonneterre J, Bosq J, Jamme P, Valent A, Gilles EM, Zukiwski AA, Fuqua SA, Lange CA, O'Shaughnessy J. Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO Open. 2016 Aug 22;1(4):e000072. doi: 10.1136/esmoopen-2016-000072. eCollection 2016. PMID: 27843626; PMCID: PMC5070234.
Copy Download .nbib Format: NLM
Share it on

ESMO Open. 2016 Aug 22;1(4):e000072. doi: 10.1136/esmoopen-2016-000072. eCollection 2016.

Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort.

ESMO open

Jacques Bonneterre, Jacques Bosq, Philippe Jamme, Alexander Valent, Erard M Gilles, Alexander A Zukiwski, Suzanne A W Fuqua, Carol A Lange, Joyce O'Shaughnessy

Affiliations

  1. Centre Oscar-Lambret, Université Lille Nord de France , Lille , France.
  2. Institut Gustave Roussy , Villejuif , France.
  3. Invivis Pharmaceuticals Inc., Bridgewater, New Jersey, USA; Arno Therapeutics, Flemington, New Jersey, USA.
  4. Arno Therapeutics , Flemington, New Jersey , USA.
  5. Baylor College of Medicine , Houston, Texas , USA.
  6. University of Minnesota Masonic Cancer Center , Minneapolis, Minnesota , USA.
  7. Baylor-Sammons Cancer Center, Texas Oncology, US Oncology , Dallas, Texas , USA.

PMID: 27843626 PMCID: PMC5070234 DOI: 10.1136/esmoopen-2016-000072

Abstract

BACKGROUND: The progesterone receptor (PR) is expressed by ∼70% of early breast tumours and is implicated in the progression of breast cancer. In cancerous tissues PR may be activated in the absence of a ligand, or when ligand concentrations are very low, resulting in aberrantly activated PR (APR). The presence of APR may indicate that patients with breast cancer are more likely to respond to antiprogestins. The aims of this study were to describe and classify the histological subnuclear morphology of active and inactive PR in archival breast cancer samples.

METHODS: Archived tumour specimens from 801 women with invasive breast cancer were collected. Tissue samples (n=789) were analysed for PR isoforms A and B (PRA and PRB), Ki67 and estrogen receptors (ERα) status, using immunohistochemistry. Medical records were used to determine human epidermal growth factor 2 (HER2) status, tumour stage and grade.

RESULTS: A total of 79% of tumours stained positive for either PRA or PRB, and of these 25% of PRA-positive and 23% of PRB-positive tumours had PR present in the activated form. APRA was associated with higher tumour grade (p=0.001). APRB was associated with a higher tumour grade (p=0.046) and a trend for a more advanced stage. Patients with PR-positive tumours treated with antiestrogens had better disease-free survival (DFS) than those with PR-negative tumours (p<0.0001). Cumulative progression rate and DFS were similar irrespective of APR status. Both APRA and APRB were independent of HER2, ERα and Ki67 expression.

CONCLUSIONS: APR had a binary mode of expression in the breast cancer specimens tested, allowing separation into two tumour subsets. APR is an independent target at the cellular and tumour level and may therefore be a suitable predictive marker for antiprogestins, such as onapristone. Using the described technique, a companion diagnostic is under development to identify APR in solid tumours.

Keywords: activated; breast cancer; onapristone; progesterone receptor

Conflict of interest statement

JBon is an investigator of an ARNO Therapeutics study and has received honoraria payments, research credits and trip fees for presentations at various congresses from Invivis Pharmaceuticals Inc. PJ h

References

  1. J Clin Pathol. 2001 Aug;54(8):624-30 - PubMed
  2. Cancer Res. 2001 Jun 1;61(11):4576-82 - PubMed
  3. Eur J Cancer. 1999 Feb;35(2):214-8 - PubMed
  4. Crit Rev Eukaryot Gene Expr. 2008;18(1):11-33 - PubMed
  5. BMC Med. 2014 Feb 20;12:32 - PubMed
  6. Mol Endocrinol. 2004 Feb;18(2):269-78 - PubMed
  7. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):449-58 - PubMed
  8. J Biol Chem. 1993 May 5;268(13):9262-6 - PubMed
  9. J Clin Oncol. 2003 May 15;21(10):1973-9 - PubMed
  10. J Clin Endocrinol Metab. 2004 Mar;89(3):1429-42 - PubMed
  11. Mol Cell Endocrinol. 2012 Jan 30;348(2):418-29 - PubMed
  12. Endocr Relat Cancer. 2012 May 03;19(3):R35-50 - PubMed
  13. Am J Clin Pathol. 2005 Jan;123(1):21-7 - PubMed
  14. Br J Cancer. 2014 Feb 4;110(3):565-72 - PubMed
  15. Nucl Recept Signal. 2009 Dec 31;7:e009 - PubMed
  16. Breast Cancer Res Treat. 2002 Mar;72(2):163-72 - PubMed
  17. Clin Cancer Res. 2004 Apr 15;10(8):2751-60 - PubMed
  18. EMBO J. 1990 May;9(5):1603-14 - PubMed
  19. World J Clin Oncol. 2014 Aug 10;5(3):248-62 - PubMed
  20. Mol Endocrinol. 2007 Jan;21(1):14-29 - PubMed
  21. Steroids. 2008 Oct;73(9-10):914-21 - PubMed
  22. Cancer Res. 1995 Nov 1;55(21):5063-8 - PubMed
  23. Carcinogenesis. 2005 Jun;26(6):1055-63 - PubMed
  24. Endocr Rev. 2013 Feb;34(1):130-62 - PubMed

Publication Types